We are live on ! Find out more
ABUS icon

Arbutus Biopharma
ABUS

48 hedge funds and large institutions have $115M invested in Arbutus Biopharma in 2016 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 14 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more capital invested

Capital invested by funds: $61.1M → $115M (+$54M)

21% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 14

7% more call options, than puts

Call options by funds: $880K | Put options by funds: $819K

6% less funds holding

Funds holding: 51 → 48 (-3)

38% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 8

Holders
48
Holders Change
-3
Holders Change %
-5.88%
% of All Funds
1.28%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.03%
New
5
Increased
17
Reduced
14
Closed
8
Calls
$880K
Puts
$819K
Net Calls
+$61K
Net Calls Change
+$151K

Top Buyers

1
QF
QVT Financial
New York
+$62.6M
2
AC
Armistice Capital
New York
+$3.88M
3
Bank of Montreal
Bank of Montreal
Ontario, Canada
+$198K
4
KPF
K2 Principal Fund
Ontario, Canada
+$172K
5
Renaissance Technologies
Renaissance Technologies
New York
+$148K

Top Sellers

1
SM
Sabby Management
Florida
-$1.16M
2
HM
HealthCor Management
New York
-$1.01M
3
IGIM
I.G. Investment Management
Manitoba, Canada
-$870K
4
SCM
Suffolk Capital Management
New York
-$496K
5
Millennium Management
Millennium Management
New York
-$430K
Name Holding Trade Value Shares
Change 		Change in
Stake
Geode Capital Management
26
Geode Capital Management
Massachusetts
$89K +$559 +143 +0.6%
Group One Trading
27
Group One Trading
Illinois
$81K +$43.4K +11,105 +90%
PP
28
PDT Partners
New York
$78K -$28.9K -7,400 -25%
Simplex Trading
29
Simplex Trading
Illinois
$72K +$54.8K +14,028 +197%
Fidelity Investments
30
Fidelity Investments
Massachusetts
$66K – – –
WS
31
Wedbush Securities
California
$58K +$18.9K +4,845 +40%
Susquehanna International Group
32
Susquehanna International Group
Pennsylvania
$51K +$15.9K +4,079 +38%
Royal Bank of Canada
33
Royal Bank of Canada
Ontario, Canada
$45K -$938 -240 -2%
State Street
34
State Street
Massachusetts
$40K -$2.65K -679 -5%
JG
35
Jefferies Group
New York
$39K – – –
CG
36
Cutler Group
California
$33K -$4.3K -1,100 -10%
UBS Group
37
UBS Group
Switzerland
$19K -$2.26K -578 -10%
BIT
38
BlackRock Institutional Trust
California
$13K +$15.2K +3,886 New
Wells Fargo
39
Wells Fargo
California
$10K – – –
Bank of America
40
Bank of America
North Carolina
$7K +$391 +100 +5%
TRCT
41
Tower Research Capital (TRC)
New York
$5K -$3.17K -810 -35%
Creative Planning
42
Creative Planning
Kansas
$3K – – –
WIC
43
Woodmont Investment Counsel
Tennessee
$3K +$3.13K +800 New
LTFS
44
Ladenburg Thalmann Financial Services
Florida
$2K +$1.95K +500 New
NFG
45
Next Financial Group
Texas
$1K – – –
US Bancorp
46
US Bancorp
Minnesota
$1K – – –
SIM
47
Sonora Investment Management
Arizona
$69 – – –
IGIM
48
I.G. Investment Management
Manitoba, Canada
– -$870K -250,000 Closed
MIG
49
Mariner Investment Group
New York
– -$313K -89,800 Closed
DCM
50
DAFNA Capital Management
California
– -$261K -75,000 Closed
1
2
3

ABUS Hedge Fund Activity: Q3 2016 in Review

48 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2016, worth a combined $115M — up 88% from $61.1M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of ABUS and 5 opened new positions — a net loss of 3 holders — while 14 trimmed existing stakes and 17 added.

The largest buyer was QVT Financial, opening a new position worth an estimated $62.6M. The largest seller was Sabby Management, cutting an estimated $1.16M.

  • 48 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2016, down from 51 in Q2 2016.
  • Funds reported $115M of Arbutus Biopharma stock for Q3 2016, up 88% quarter-over-quarter.
  • 5 funds opened new Arbutus Biopharma positions in Q3 2016 and 8 closed out, a net change of -3 holders.
  • The largest Arbutus Biopharma buyer in Q3 2016 was QVT Financial, an estimated $62.6M added.
  • The largest Arbutus Biopharma seller in Q3 2016 was Sabby Management, an estimated $1.16M sold.

Based on aggregated 13F filings for Q3 2016.